The national project "New technologies for saving health"

On January 1, 2025, the national project "New Technologies for Saving Health" was launched, which is aimed at developing medical science, creating innovative medicines and medical products, active longevity and disease prevention, as well as the massive introduction of digital technologies and remote medical care.

The national project is aimed at achieving technological leadership in the field of medical technologies, production of medicines and medical products by 2030.

It is planned to increase the share of domestic production of medicines to 90 %, and medical products to 40 %.

The national project consists of five federal projects:

• "Management of Medical Science";
• "Medical development technologies";
• "Biomedical and cognitive technologies of the future";
• "Regenerative biomedicine, preventive medicine technologies, ensuring active and healthy longevity";
• "Development of production of the most demanded medicines and medical devices".

 It is planned to allocate 210 billion rubles for the implementation of the project.  60 billion rubles are from the federal budget, and 151 billion rubles are from extra-budgetary sources.

At a meeting of the committee on the national project "New technologies for saving health", which was held on 08.08.2025 under the leadership of Deputy Prime Minister Tatyana Golikova with the participation of the Head of the Ministry of Health Mikhail Murashko, representatives of the Ministry of Industry and Trade, the Ministry of Education and Science, the Ministry of Finance, the FMBA, Roszdravnadzor and other departments, it became known which initiatives will be supported at the first stage of the national project — from 2025 to 2027.

In the next two years, about 30 clinical trials of medicines and medical devices will be implemented, medical technologies and products used in neurodegenerative diseases and cognitive impairments will be put into practice.

During the same period of time, it is planned to introduce into practice 7 biomedical cellular products (BMCP), as well as tissue engineering products in the framework of regenerative biomedicine for the treatment of infertility in men, the effects of injuries to large joints, spinal cord.

According to the results of the first half of the year, within the framework of the project "Development of the production of the most in-demand medicines and medical devices", the line of medical products was expanded to 550 units and the number of domestically produced drugs included in the List of VED was increased to eight INN.